Journal
Research and Practice in Thrombosis and Haemostasis
Publication Date
11-1-2024
Volume
8
Issue
8
First Page
102615
Document Type
Open Access Publication
DOI
10.1016/j.rpth.2024.102615
Rights and Permissions
Leavitt AD, Mahlangu J, Raheja P, Symington E, Quon DV, Giermasz A, López Fernández MF, Kenet G, Lowe G, Key NS, Millar CM, Pipe SW, Madan B, Chou SC, Klamroth R, Mason J, Chambost H, Peyvandi F, Majerus E, Pepperell D, Rivat C, Yu H, Robinson TM, Ozelo MC. Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial. Res Pract Thromb Haemost. 2024 Oct 30;8(8):102615. doi: 10.1016/j.rpth.2024.102615. © 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis. This is an open access article under the CC BYNC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
Leavitt, Andrew D; Majerus, Elaine; and et al., "Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial." Research and Practice in Thrombosis and Haemostasis. 8, 8. 102615 (2024).
https://digitalcommons.wustl.edu/oa_4/6976
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
